Wondershare UniConverter12 Released: A Complete Video Toolbox - Become More Powerful
31.8.2020 11:15:00 EEST | Business Wire | Press release
While working with videos, several editing and other functions are needed like conversion, downloading, recording, cutting, cropping, editing metadata, compression, and others. To get all these tasks done like pro several editing software are available and one such professional tool is Wondershare UniConverter . Formerly known as Wondershare Video Converter Ultimate, the latest version, UniConverter v12, hit the market on July 08, 2020. The latest version claims to offer drastically improved performance of the “Video Converter” tool.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200831005217/en/
Wondershare UniConverter Version 12 (Photo: Business Wire)
Part 1: Key features of Wondershare UniConverter software
1. Video Conversion: With the availability of different video formats and devices, conversion becomes an essential requirement that Wondershare UniConverter software can easily take care of. With support to over 1000 formats and devices, you will not face any playback issues with your video files as they can be quickly converted to the desired format.
Video conversion takes place without any quality loss and there is also an option to merge multiple files.
2. Edit Video: Video customization is important to enhance your overall video and make it look presentable. Wonderware comes loaded with a complete built-in editor that supports all required tools like cutting, cropping, adding watermark, adding special effects, and more.
3. Burn video to DVD: To create a physical backup and to play your digital files on a DVD player, the software supports the function where your video files can be quickly converted into a DVD.
4. Compress Video Size: When you are finding it difficult to accommodate your video files, compression comes to the rescue. Using Wondershare UniConverter video files in almost all formats can be quickly resized and compressed without losing any quality.
5. Downloading and recording: For offline playback of your videos on an array of devices, the software allows video downloads from over 10,000 sites including popular names like DailyMotion, YouTube, Vimeo, and more.
6. Other Features: Several other features are also supported by the software like fixing metadata, VR conversion, GIF-making and more.
Part 2: Some of the mention-worthy advancements that Wondershare promises the users will get with UniConverter v12 include:
- Designed using the industry leading APEXTRANS technology exclusive to Wondershare, the updated app is said to convert or compress the videos with zero picture quality deterioration. If the claims are correct, in contrast to its predecessor, the improved GPU acceleration exploits the multicore processor to its maximum.
- The program allows lossless batch conversions where setting global output parameters, and multiple videos can be converted to a relevant format in a single go with absolutely no quality loss.
- Otherwise, the app can convert 4K and 8K videos and can perform batch conversion for those large files.
- HEVC is another format type that UniConverter v12 supports and claims to convert the videos with no loss of picture quality.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200831005217/en/
Contact information
Name: Tyler Jäger
Email: pr@wondershare.de
Address: Vancouver, Canada
Phone number: +86 755 86665000
Website:
Germany: https://uniconverter.wondershare.de/
France: https://uniconverter.wondershare.fr/
Italy: https://uniconverter.wondershare.it/
Spain: https://uniconverter.wondershare.es/
Netherlands: https://videoconverter.wondershare.com/nl/
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom